ProQR Therapeutics (PRQR) Net Cash Flow (2013 - 2022)

ProQR Therapeutics' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$308114.7 for Q4 2022.

• In Q4 2022, Net Cash Flow fell 100.88% year-over-year to -$308114.7; the TTM figure through Dec 2025 stood at $0.0 (changed 0.0% YoY), while the FY2025 annual figure was -$64.8 million, down 303.35% from the prior year.
• Net Cash Flow came in at -$308114.7 for Q4 2022 at ProQR Therapeutics, up from -$59.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $93.9 million in Q3 2018 to a low of -$59.9 million in Q3 2022.
• A 5-year average of $5.1 million and a median of -$3.4 million in 2018 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 254392015.15% in 2018 and slumped 3560227.31% in 2019, its largest moves.
• ProQR Therapeutics' Net Cash Flow stood at -$9312.7 in 2018, then surged by 451869.13% to $42.1 million in 2019, then plunged by 133.09% to -$13.9 million in 2020, then jumped by 351.13% to $35.0 million in 2021, then tumbled by 100.88% to -$308114.7 in 2022.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$308114.7, -$59.9 million, and -$16.5 million for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison